Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- MRNS -14.3%, ASNA -13.2%, FRPT -12.5%, NLS -6.7%, SNDX -5.6%, FATE -5.5%,TGT -4%, STRL -2.4%, BLRX -1.8%, RYI -1%
M&A news:
- JWN -2.2% (Nordstrom announces the receipt and rejection of an indicative proposal to acquire the company; Nordstrom family offered $50.00/share)
Other news:
- GLYC -17.2% (GlycoMimetics announces its design for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate GMI-1271 in combination with MEC Mitoxantrone, etoposide and Ara-C or in combination with fludarabine, cytosine arabinoside and idarubicin in individuals with relapsed/refractory acute myeloid leukemi )
- SCYX -11.2% ( commences an underwritten public offering of shares of its common stock and warrants)
- ARES -9.1% (announces 15 mln share offering -10 mln by selling shareholder and 5 mln by the company)
- UQM -6.2% (UQM Technologies and CNHTC have withdrawn their CFIUS Application)
- NYRT -3.8% (announces 1:10 reverse split effective at approximately 5:00pm ET on March 15, 2018 )
- GTHX -1.5% (filed for 3 mln share common stock offering)
- CDEV -1.5% (commences an underwritten public offering of 25,000,000 shares by selling shareholders)
- TRU -0.8% (pricing of underwritten secondary offering by certain of its stockholders of 19,889,564 shares of common stock )
Analyst comments:
- GRUB -2.9% (downgraded to Neutral from Buy at BofA/Merrill)
- CNI -1.1% (downgraded to Underperform from Neutral at BofA/Merrill)
- SEP -0.8% (downgraded to Hold from Buy at Stifel)